Crispr sam biosensor cell lines and methods of use thereof
AssigneeDecibel Therapeutics, Inc.
InventorsMeghan DRUMMOND SAMUELSON, Leah SABIN, Sarah CANCELARICH
Life of this patent
Estimating the term…
Abstract
Disclosed are cell lines that stably express CRISPR SAM complex which comprise a gRNA that specifically targets a promoter of a gene, wherein the gene is not normally expressed in said cell. Also disclosed are methods of measuring the ability of a vector to transfer a nucleic acid molecule into such cell lines.
Claims32
A cell that stably expresses a CRISPR/Cas9 Synergistic Activation Mediator complex (“CRISPR SAM complex”), wherein the CRISPR complex comprises a gRNA that specifically targets a promoter of a gene and wherein the gene is not normally expressed in said cell.
An HK231 cell line that stably expresses a CRISPR/Cas9 Synergistic Activation Mediator complex (“CRISPR SAM complex”), wherein the CRISPR SAM complex comprises a gRNA that specifically targets mMyo15 promoter, wherein:
- a) the CRISPR SAM complex comprises a Cas9-VP64 fusion protein, wherein the Cas9-VP64 fusion protein has an eliminated nuclease activity;
- and
- b) the gRNA comprises a nucleic acid sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO:
- 77).
A gRNA sequence comprising a nucleic acid sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO:
- 77).
A gRNA sequence comprising a nucleic acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to CACAGGGGGACAUCAUCUAC (SEQ ID NO:
- 77).
A gRNA sequence of CACAGGGGGACAUCAUCUAC (SEQ ID NO:
- 77).
Dependencies are inferred from the claim text.